{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:58:13Z","timestamp":1792407493005,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11892-020-01313-z","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:02:41Z","timestamp":1591747361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Purine Metabolite Signatures and Type 2 Diabetes: Innocent Bystanders or Actionable Items?"],"prefix":"10.1007","volume":"20","author":[{"given":"Giulio R.","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1313_CR1","unstructured":"Hippocrates. The genuine works of Hippocrates. Translated from the Greek with a preliminary discourse and annotations by Francis Adams. Wood, New York. 1986;I, II."},{"key":"1313_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJM189403291301303","volume":"130","author":"EP Joslin","year":"1894","unstructured":"Joslin EP. Pathology of diabetes mellitus. Boston Med Surg J. 1894;130:309\u201312.","journal-title":"Boston Med Surg J"},{"key":"1313_CR3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/BF01726343","volume":"2","author":"E Kylin","year":"1923","unstructured":"Kylin E. \u00dcber die Essentielle Hypertonie als Teilsymptom Einer Funktionellen Krankheit. Klin Wochenschr. 1923;2:2064\u20136.","journal-title":"Klin Wochenschr"},{"issue":"2","key":"1313_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jama.1966.03110020065023","volume":"197","author":"D Berkowitz","year":"1966","unstructured":"Berkowitz D. Gout, hyperlipidemia, and diabetes interrelationships. JAMA. 1966;197(2):77\u201380.","journal-title":"JAMA."},{"issue":"21","key":"1313_CR5","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1001\/jama.1991.03470210076036","volume":"266","author":"F Facchini","year":"1991","unstructured":"Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008\u201311.","journal-title":"JAMA."},{"issue":"1","key":"1313_CR6","first-page":"25","volume":"78","author":"H Vuorinen-Markkola","year":"1994","unstructured":"Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78(1):25\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1313_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.117.10370","volume":"71","author":"M Kuwabara","year":"2018","unstructured":"Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71(1):78\u201386.","journal-title":"Hypertension."},{"issue":"6","key":"1313_CR8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12120","volume":"274","author":"H Wang","year":"2013","unstructured":"Wang H, Jacobs DR Jr, Gaffo AL, Gross MD, Goff DC Jr, Carr JJ. Longitudinal association between serum urate and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Intern Med. 2013;274(6):594\u2013609.","journal-title":"J Intern Med"},{"issue":"4","key":"1313_CR9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(97)00262-3","volume":"30","author":"SD Anker","year":"1997","unstructured":"Anker SD, Clark AL, Kemp M, Salsbury C, Teixeira MM, Hellewell PG, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997;30(4):997\u20131001.","journal-title":"J Am Coll Cardiol"},{"issue":"1\u20132","key":"1313_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2005.07.027","volume":"86","author":"WL Nyhan","year":"2005","unstructured":"Nyhan WL. Disorders of purine and pyrimidine metabolism. Mol Genet Metab. 2005;86(1\u20132):25\u201333.","journal-title":"Mol Genet Metab"},{"key":"1313_CR11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1042\/bj0140721","volume":"14","author":"FG Hopkins","year":"1920","unstructured":"Hopkins FG. Note on the vitamin content of milk. Biochem J. 1920;14:721\u20134.","journal-title":"Biochem J"},{"issue":"2","key":"1313_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1042\/bj1080349","volume":"108","author":"ED Corte","year":"1968","unstructured":"Corte ED, Stirpe F. Regulation of xanthine oxidase in rat liver: modifications of the enzyme activity of rat liver supernatant on storage at 20 degrees. Biochem J. 1968;108(2):349\u201351.","journal-title":"Biochem J"},{"issue":"13","key":"1313_CR13","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1111\/j.1742-4658.2008.06489.x","volume":"275","author":"T Nishino","year":"2008","unstructured":"Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008;275(13):3278\u201389.","journal-title":"FEBS J"},{"issue":"1","key":"1313_CR14","first-page":"48","volume":"74","author":"A Sarnesto","year":"1996","unstructured":"Sarnesto A, Linder N, Raivio KO. Organ distribution and molecular forms of human xanthine dehydrogenase\/xanthine oxidase protein. Lab Investig. 1996;74(1):48\u201356.","journal-title":"Lab Investig"},{"issue":"38","key":"1313_CR15","doi-asserted-by":"crossref","first-page":"27138","DOI":"10.1074\/jbc.M113.485094","volume":"288","author":"Y Tsushima","year":"2013","unstructured":"Tsushima Y, Nishizawa H, Tochino Y, Nakatsuji H, Sekimoto R, Nagao H, et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem. 2013;288(38):27138\u201349.","journal-title":"J Biol Chem"},{"issue":"8","key":"1313_CR16","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1074\/jbc.274.8.4561","volume":"274","author":"CM Harris","year":"1999","unstructured":"Harris CM, Sanders SA, Massey V. Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase. J Biol Chem. 1999;274(8):4561\u20139.","journal-title":"J Biol Chem"},{"issue":"11","key":"1313_CR17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1096\/fasebj.9.11.7649415","volume":"9","author":"R Hille","year":"1995","unstructured":"Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J. 1995;9(11):995\u20131003.","journal-title":"FASEB J"},{"issue":"10","key":"1313_CR18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"1313_CR19","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/S0021-9258(18)63065-0","volume":"245","author":"V Massey","year":"1970","unstructured":"Massey V, Komai H, Palmer G, Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970;245(11):2837\u201344.","journal-title":"J Biol Chem"},{"issue":"20","key":"1313_CR20","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.lfs.2006.06.024","volume":"79","author":"A Casillas-Ramirez","year":"2006","unstructured":"Casillas-Ramirez A, Mosbah IB, Ramalho F, Rosello-Catafau J, Peralta C. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci. 2006;79(20):1881\u201394.","journal-title":"Life Sci"},{"issue":"20","key":"1313_CR21","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763\u201371.","journal-title":"Circulation."},{"issue":"6","key":"1313_CR22","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","volume":"62","author":"C Xu","year":"2015","unstructured":"Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 2015;62(6):1412\u20139.","journal-title":"J Hepatol"},{"issue":"12","key":"1313_CR23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595\u2013607.","journal-title":"Diabetes."},{"issue":"1","key":"1313_CR24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1993.tb00700.x","volume":"234","author":"I Zavaroni","year":"1993","unstructured":"Zavaroni I, Mazza S, Fantuzzi M, Dall\u2019Aglio E, Bonora E, Delsignore R, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med. 1993;234(1):25\u201330.","journal-title":"J Intern Med"},{"issue":"9","key":"1313_CR25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/BF00296994","volume":"30","author":"M Modan","year":"1987","unstructured":"Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid--a facet of hyperinsulinaemia. Diabetologia. 1987;30(9):713\u20138.","journal-title":"Diabetologia."},{"key":"1313_CR26","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kimberly WT, O\u2019Sullivan JF, Nath AK, Keyes M, Shi X, Larson MG, et al. Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight. 2017;2(9):e92989 This study showed a strong association between sUA and other purine metabolites with features of the metabolic syndrome.","DOI":"10.1172\/jci.insight.92989"},{"issue":"5","key":"1313_CR27","doi-asserted-by":"crossref","first-page":"e10883","DOI":"10.1371\/journal.pone.0010883","volume":"5","author":"WE Gall","year":"2010","unstructured":"Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. alpha-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883.","journal-title":"PLoS One"},{"issue":"12","key":"1313_CR28","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.2337\/db13-0570","volume":"62","author":"C Menni","year":"2013","unstructured":"Menni C, Fauman E, Erte I, Perry JR, Kastenmuller G, Shin SY, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62(12):4270\u20136.","journal-title":"Diabetes."},{"issue":"10","key":"1313_CR29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1313_CR30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2337\/db18-1198","volume":"68","author":"DB Harmon","year":"2019","unstructured":"\u2022\u2022 Harmon DB, Mandler WK, Sipula IJ, Dedousis N, Lewis SE, Eckels JT, et al. Hepatocyte-specific ablation or whole-body inhibition of xanthine oxidoreductase in mice corrects obesity-induced systemic hyperuricemia without improving metabolic abnormalities. Diabetes. 2019;68(6):1221\u20139 This study demonstrated that liver-specific ablation of XOR or systemic pharmacologic inhibition of XOR does not result in improvement in IR, despite reduction of UA and XOR activity, both in the liver and plasma.","journal-title":"Diabetes"},{"issue":"10","key":"1313_CR31","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","volume":"62","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62(10):3307\u201315.","journal-title":"Diabetes."},{"issue":"4","key":"1313_CR32","first-page":"255","volume":"10","author":"S Yamashita","year":"1986","unstructured":"Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10(4):255\u201364.","journal-title":"Int J Obes"},{"issue":"1","key":"1313_CR33","doi-asserted-by":"crossref","first-page":"11529","DOI":"10.1038\/s41598-018-29955-w","volume":"8","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D\u2019Addato S, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8(1):11529.","journal-title":"Sci Rep"},{"issue":"9","key":"1313_CR34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/dc09-0288","volume":"32","author":"S Kodama","year":"2009","unstructured":"Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737\u201342.","journal-title":"Diabetes Care"},{"issue":"8","key":"1313_CR35","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.2337\/db14-0742","volume":"64","author":"I Sluijs","year":"2015","unstructured":"Sluijs I, Holmes MV, van der Schouw YT, Beulens JW, Asselbergs FW, Huerta JM, et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes. 2015;64(8):3028\u201336.","journal-title":"Diabetes."},{"issue":"4","key":"1313_CR36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jacc.2015.10.086","volume":"67","author":"T Keenan","year":"2016","unstructured":"Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal assessment of serum Urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1313_CR37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ijo.2009.259","volume":"34","author":"SE Perez-Pozo","year":"2010","unstructured":"Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, Lillo JL. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes. 2010;34(3):454\u201361.","journal-title":"Int J Obes"},{"issue":"8","key":"1313_CR38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924\u20139.","journal-title":"J Investig Med"},{"issue":"2","key":"1313_CR39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","volume":"71","author":"MA Schwarzschild","year":"2014","unstructured":"Parkinson Study Group S-PDI, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141\u201350.","journal-title":"JAMA Neurol"},{"key":"1313_CR40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ebiom.2018.10.039","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, et al. Dissociation between urate and blood pressure in mice and in people with early Parkinson\u2019s disease. EBioMedicine. 2018;37:259\u201368.","journal-title":"EBioMedicine."},{"issue":"4","key":"1313_CR41","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/HYPERTENSIONAHA.109.135152","volume":"54","author":"T Ohtsubo","year":"2009","unstructured":"Ohtsubo T, Matsumura K, Sakagami K, Fujii K, Tsuruya K, Noguchi H, et al. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension. 2009;54(4):868\u201376.","journal-title":"Hypertension."},{"issue":"1","key":"1313_CR42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/ATVBAHA.113.302214","volume":"34","author":"N Murakami","year":"2014","unstructured":"Murakami N, Ohtsubo T, Kansui Y, Goto K, Noguchi H, Haga Y, et al. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes. Arterioscler Thromb Vasc Biol. 2014;34(1):44\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1313_CR43","doi-asserted-by":"crossref","first-page":"G42","DOI":"10.1152\/ajpgi.00443.2014","volume":"309","author":"Y Nakatsu","year":"2015","unstructured":"Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015;309(1):G42\u201351.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"1313_CR44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7326\/0003-4819-34-6-1421","volume":"34","author":"MM Gertler","year":"1951","unstructured":"Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34(6):1421\u201331.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1313_CR45","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2005.07.068","volume":"96","author":"M Kato","year":"2005","unstructured":"Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96(11):1576\u20138.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1313_CR46","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/HJH.0000000000000224","volume":"32","author":"F Mallamaci","year":"2014","unstructured":"Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens. 2014;32(8):1621\u20138 discussion 8.","journal-title":"J Hypertens"},{"issue":"23","key":"1313_CR47","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508\u201316.","journal-title":"Circulation."},{"key":"1313_CR48","doi-asserted-by":"crossref","first-page":"f4262","DOI":"10.1136\/bmj.f4262","volume":"347","author":"TM Palmer","year":"2013","unstructured":"Palmer TM, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor DA, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262.","journal-title":"BMJ."},{"key":"1313_CR49","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","volume":"4","author":"J Nomura","year":"2014","unstructured":"Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014;4:4554.","journal-title":"Sci Rep"},{"issue":"2","key":"1313_CR50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/ATVBAHA.111.234559","volume":"32","author":"A Kushiyama","year":"2012","unstructured":"Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012;32(2):291\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"1313_CR51","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"1313_CR52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"1313_CR53","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"\u2022\u2022 White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200\u201310 Results of this RCT demonstrated that Febuxostat is noninferior to Allopurinol for the composite MACE outcome but increases CVD mortality and all-cause mortality.","journal-title":"N Engl J Med"},{"issue":"7","key":"1313_CR54","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019;140(7):e294\u2013324.","journal-title":"Circulation."},{"issue":"9","key":"1313_CR55","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s00125-019-4926-x","volume":"62","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550\u201360.","journal-title":"Diabetologia."},{"issue":"15","key":"1313_CR56","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","volume":"107","author":"SD Anker","year":"2003","unstructured":"Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107(15):1991\u20137.","journal-title":"Circulation."},{"issue":"24","key":"1313_CR57","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jacc.2013.07.074","volume":"62","author":"BR Szwejkowski","year":"2013","unstructured":"Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"1313_CR58","unstructured":"\u2022\u2022 Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum Urate lowering with allopurinol and kidney function in type 1 diabetes. New Engl J Med. 2020;In press. The Preventing Early Renal Loss in diabetes (PERL) RCT showed that 3-year treatment with Allopurinol did not modify the progression of early-to-moderate diabetic kidney disease in patients with type 1 diabetes of long duration, when compared with the placebo."},{"issue":"8","key":"1313_CR59","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2337\/db12-0754","volume":"62","author":"JE Ho","year":"2013","unstructured":"Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, et al. Metabolite profiles during oral glucose challenge. Diabetes. 2013;62(8):2689\u201398.","journal-title":"Diabetes."},{"issue":"1","key":"1313_CR60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.celrep.2015.08.072","volume":"13","author":"JR Gooding","year":"2015","unstructured":"Gooding JR, Jensen MV, Dai X, Wenner BR, Lu D, Arumugam R, et al. Adenylosuccinate is an insulin secretagogue derived from glucose-induced purine metabolism. Cell Rep. 2015;13(1):157\u201367.","journal-title":"Cell Rep"},{"issue":"7531","key":"1313_CR61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature13816","volume":"516","author":"T Gnad","year":"2014","unstructured":"Gnad T, Scheibler S, von Kugelgen I, Scheele C, Kilic A, Glode A, et al. Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature. 2014;516(7531):395\u20139.","journal-title":"Nature."},{"issue":"1","key":"1313_CR62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41467-017-00551-2","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu Z, Yan S, Wang J, Xu Y, Wang Y, Zhang S, et al. Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis. Nat Commun. 2017;8(1):584.","journal-title":"Nat Commun"},{"issue":"1","key":"1313_CR63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cmet.2016.09.018","volume":"25","author":"CB Newgard","year":"2017","unstructured":"Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43\u201356.","journal-title":"Cell Metab"},{"issue":"10","key":"1313_CR64","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1210\/jc.2019-00822","volume":"104","author":"F Ottosson","year":"2019","unstructured":"Ottosson F, Smith E, Gallo W, Fernandez C, Melander O. Purine metabolites and carnitine biosynthesis intermediates are biomarkers for incident type 2 diabetes. J Clin Endocrinol Metab. 2019;104(10):4921\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1313_CR65","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41598-019-39441-6","volume":"9","author":"C Papandreou","year":"2019","unstructured":"Papandreou C, Li J, Liang L, Bullo M, Zheng Y, Ruiz-Canela M, et al. Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism. Sci Rep. 2019;9(1):2892.","journal-title":"Sci Rep"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-020-01313-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-020-01313-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-020-01313-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:39:05Z","timestamp":1625125145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-020-01313-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s11892-020-01313-z","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"10 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"30"}}